| Autor: |
Oduyebo T; Zika Virus Response Team, CDC., Polen KD; Zika Virus Response Team, CDC., Walke HT; Zika Virus Response Team, CDC., Reagan-Steiner S; Zika Virus Response Team, CDC., Lathrop E; Zika Virus Response Team, CDC., Rabe IB; Zika Virus Response Team, CDC., Kuhnert-Tallman WL; Zika Virus Response Team, CDC., Martin SW; Zika Virus Response Team, CDC., Walker AT; Zika Virus Response Team, CDC., Gregory CJ; Zika Virus Response Team, CDC., Ades EW; Zika Virus Response Team, CDC., Carroll DS; Zika Virus Response Team, CDC., Rivera M; Zika Virus Response Team, CDC., Perez-Padilla J; Zika Virus Response Team, CDC., Gould C; Zika Virus Response Team, CDC., Nemhauser JB; Zika Virus Response Team, CDC., Ben Beard C; Zika Virus Response Team, CDC., Harcourt JL; Zika Virus Response Team, CDC., Viens L; Zika Virus Response Team, CDC., Johansson M; Zika Virus Response Team, CDC., Ellington SR; Zika Virus Response Team, CDC., Petersen E; Zika Virus Response Team, CDC., Smith LA; Zika Virus Response Team, CDC., Reichard J; Zika Virus Response Team, CDC., Munoz-Jordan J; Zika Virus Response Team, CDC., Beach MJ; Zika Virus Response Team, CDC., Rose DA; Zika Virus Response Team, CDC., Barzilay E; Zika Virus Response Team, CDC., Noonan-Smith M; Zika Virus Response Team, CDC., Jamieson DJ; Zika Virus Response Team, CDC., Zaki SR; Zika Virus Response Team, CDC., Petersen LR; Zika Virus Response Team, CDC., Honein MA; Zika Virus Response Team, CDC., Meaney-Delman D; Zika Virus Response Team, CDC. |
| Abstrakt: |
CDC has updated the interim guidance for U.S. health care providers caring for pregnant women with possible Zika virus exposure in response to 1) declining prevalence of Zika virus disease in the World Health Organization's Region of the Americas (Americas) and 2) emerging evidence indicating prolonged detection of Zika virus immunoglobulin M (IgM) antibodies. Zika virus cases were first reported in the Americas during 2015-2016; however, the incidence of Zika virus disease has since declined. As the prevalence of Zika virus disease declines, the likelihood of false-positive test results increases. In addition, emerging epidemiologic and laboratory data indicate that, as is the case with other flaviviruses, Zika virus IgM antibodies can persist beyond 12 weeks after infection. Therefore, IgM test results cannot always reliably distinguish between an infection that occurred during the current pregnancy and one that occurred before the current pregnancy, particularly for women with possible Zika virus exposure before the current pregnancy. These limitations should be considered when counseling pregnant women about the risks and benefits of testing for Zika virus infection during pregnancy. This updated guidance emphasizes a shared decision-making model for testing and screening pregnant women, one in which patients and providers work together to make decisions about testing and care plans based on patient preferences and values, clinical judgment, and a balanced assessment of risks and expected outcomes. |
